1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
June 2026 in “Saudi Medical Horizons Journal” JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
10 citations
,
January 2018 in “Functional Foods in Health and Disease” Black raspberry extract may help with hair growth, skin whitening, and weight loss.
3 citations
,
January 2021 in “Molecular genetics & genomic medicine” The study found two new mutations in a Chinese patient with severe biotinidase deficiency.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
32 citations
,
April 2011 in “Journal of the American Academy of Dermatology” Erlotinib may cause scarring hair loss.
8 citations
,
November 2024 in “EMBO Molecular Medicine” Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.
November 2022 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” Phosphatidylinositol 4-kinases are crucial for root growth, defense, and immunity in Arabidopsis thaliana.
December 2025 in “International Journal of Surgery” GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” Erlotinib can cause nonscarring hair loss and itchy skin.
15 citations
,
April 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” A3B5 can reduce skin pigmentation and slow melanoma growth.
10 citations
,
January 2008 in “Biological and Pharmaceutical Bulletin” t-Flavanone may help hair growth by reducing a specific protein's activity in skin cells.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
24 citations
,
January 2023 in “Cancer Research” AMPK activation may reduce melanoma risk in red-haired individuals.